Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 19/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.56 |
| ▸ | WEE1 | P30291 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770196 | 1.00 | KDR (1.00) | KDRAURKBLRRK2AURKALCK | |
| SCHEMBL3780241 | 0.90 | KDR (0.81) | KDRAURKB | |
| SCHEMBL3776042 | 0.90 | KDR (0.81) | KDRAURKB | |
| SCHEMBL3780202 | 0.88 | AURKB (0.80) | KDRAURKBLRRK2AURKALCK | |
| SCHEMBL3775176 | 0.88 | AURKB (0.80) | KDRAURKBLRRK2AURKALCK | |
| SCHEMBL3773548 | 0.87 | AURKB (0.77) | KDRAURKBAURKA | |
| SCHEMBL3766997 | 0.87 | AURKB (0.77) | KDRAURKBAURKA | |
| SCHEMBL3783087 | 0.86 | AURKB (1.00) | KDRAURKBAURKALCKPDGFRA | |
| SCHEMBL3774127 | 0.86 | AURKB (1.00) | KDRAURKBAURKALCKPDGFRA | |
| SCHEMBL3775089 | 0.86 | AURKB (1.00) | KDRAURKBAURKALCKPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | claimed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | KDR 38/4885AURKB 3/4885LRRK2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.